IFPMA’s Post

📢 Live Stream: Ensuring Sustainable Access to Effective Antibiotics: The Path from #UNGA to Impact The upcoming United Nations General Assembly High-Level Meeting on Antimicrobial Resistance (AMR) presents a critical opportunity to establish a clear roadmap for effective and sustainable interventions to tackle this pressing global health threat. To elevate the conversation around the scale and impact of #AMR, and to emphasize the urgent need for political commitment, realistic targets, accountability frameworks, and funding, a coalition of organizations—including One Health Trust, Africa Centres for Disease Control and Prevention, United States Centers for Disease Control and Prevention, IFPMA, Global AMR R&D Hub, FIND, AMR Action Fund, The International Centre for Antimicrobial Resistance Solutions (ICARS), the Infectious Diseases Society of America, and the Bill & Melinda Gates Foundation—has organized a side event on AMR during the #UNGA. 🗓️ September 22nd, 5-7pm (EST) 📍 Online / free Info & registration ➡ https://lnkd.in/em78CF95

🌍 Join us virtually for the 2024 The Lancet series premiere on #AMR!   The global fight for better health outcomes and decades of progress in treating infections are at risk due to antimicrobial resistance (AMR). The United Nations General Assembly (UNGA) will hold a high-level meeting in September 2024 to discuss this present and growing threat. To bolster the momentum gained from this watershed moment in the battle to control AMR, a Lancet series was commissioned to provide crucial data, evidence, and policy recommendations to serve as the cornerstone for a U.N. resolution addressing AMR.   In the series, Aislinn Cook, Prof Koen Pouwels and Prof Mike Sharland and co-authors touch on the current burden of AMR, the importance of expanding antibiotic access and innovation, and the need to promote the establishment of global targets and get politicians on board.   To commemorate the series, One Health Trust, FIND, IFPMA,  The International Centre for Antimicrobial Resistance Solutions (ICARS), AMR Action Fund, Africa CDC, Global AMR R&D Hub, and Infectious Diseases Society of America are holding a symposium, gathering authors, experts, policymakers, and civil society to discuss AMR's impact, the importance of antibiotic access, and the push for global targets. While the in-person event is invitation-only, catch the live stream to be part of this vital conversation! Register here: https://lnkd.in/enSbiRk8 Date and time: May 28, 6:30 PM - 8:30 PM (GMT+2, Geneva, Switzerland) Read more here: https://lnkd.in/eezAvfF4   #ADILA

This fall, join the largest commercial gathering of AMR and infectious disease stakeholders at the World Antimicrobial Resistance Congress and co-located Disease Prevention & Control Summit – returning to the Pennsylvania Convention Center September 5-6 for our biggest year yet❗️ 🗣️ Tackle the critical issue of #antimicrobialresistance and dive into groundbreaking discussions on... 𝗔𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁: Explore the latest advancements and breakthroughs in antibiotic research. 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀: Discover innovative diagnostic tools that are revolutionizing how we detect infections and combat resistance. 𝗜𝗺𝗽𝗮𝗰𝘁: Understand the global impact of AMR on health, economies, and societies. 𝗣𝗼𝗹𝗶𝗰𝘆 & 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀: Learn about essential policies and awareness campaigns driving the fight against AMR. 𝗢𝗻𝗲 𝗛𝗲𝗮𝗹𝘁𝗵: Embrace the One Health approach, connecting human, animal, and environmental health to curb AMR. 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗦𝗵𝗼𝘄𝗰𝗮𝘀𝗲: Witness cutting-edge innovations and solutions presented by leading experts. 𝗔𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰 𝗦𝘁𝗲𝘄𝗮𝗿𝗱𝘀𝗵𝗶𝗽: Discuss strategies for responsible antibiotic use to preserve their effectiveness. 𝗔𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻: Delve into the challenges and opportunities in bringing new antibiotics to market. ... 𝘢𝘯𝘥 𝘮𝘰𝘳𝘦! Claim your 𝟲𝟬% 𝗼𝗳𝗳 𝘁𝗶𝗰𝗸𝗲𝘁 and join us in the combat against antimicrobial resistance to ensure a healthier future for all! 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗮𝗻𝗱 𝘀𝗮𝘃𝗲 $𝟱𝟵𝟱 𝗼𝗻 𝘆𝗼𝘂𝗿 𝘁𝗶𝗰𝗸𝗲𝘁 𝘁𝗼𝗱𝗮𝘆: https://lnkd.in/eWcqExVC 𝗔𝗰𝗮𝗱𝗲𝗺𝗶𝗮 𝗮𝗻𝗱 𝗵𝗼𝘀𝗽𝗶𝘁𝗮𝗹𝘀, 𝘀𝗲𝗰𝘂𝗿𝗲 𝘆𝗼𝘂𝗿 𝗙𝗥𝗘𝗘 𝗽𝗮𝘀𝘀 𝗵𝗲𝗿𝗲:  https://lnkd.in/eDJXVNQh 𝘓𝘰𝘰𝘬𝘪𝘯𝘨 𝘵𝘰 𝘨𝘦𝘵 𝘪𝘯𝘷𝘰𝘭𝘷𝘦𝘥? 𝗜𝗻𝗾𝘂𝗶𝗿𝗲 𝘁𝗼 𝘀𝗽𝗼𝗻𝘀𝗼𝗿 𝗵𝗲𝗿𝗲: https://lnkd.in/eCHDPvP9 #WorldAMRCongress #AMR #AntibioticDevelopment #diagnostics #OneHealth #AntibioticStewardship #AntibioticCommercialization

Antimicrobial resistance (AMR) is a pressing global issue, and it’s here. Global Coalition on Aging and Infectious Diseases Society of America are pleased to announce the launch of the 2024 AMR Preparedness Index Progress Report, where we evaluate eleven of the world’s largest economies on their progress toward tackling AMR. With this year’s United Nations General Assembly High-Level Meeting on AMR and on the heels of a global pandemic, there has never been a time more urgent than now for countries to recommit to united action against AMR. Check out the full report https://lnkd.in/er2h6Cn9 Many thanks to John Rex, Andrew Jack, Danielle P., Dame Sally Davies, Andre Luiz de Abreu, Maria Jose Ruiz Alvarez, Michael Hodin, Matt McEnany, Neil Clancy, Luka Šrot, Ana-Maria N., Olivia Canie, Jeremy Knox, Caline Mattar, Yui Kohno, Neda Milevska Kostova, David Elin, Antonio Leitão, Ramanan Laxminarayan, Matthew Renwick, Abigail Herron, Claire Oxlade, Sagar Sane, Kendra Gordillo, Caroline Hubbard, and so many countless others who contributed to the creation and launch of this important report.

[In the Media] “The Basic Policy on Economic and Fiscal Management 2024 Should Include Japan’s Role as a Global Leader in Addressing Antimicrobial Resistance (AMR)” (June 19, 2024) On June 11, 2024, AMR Alliance Japan presented recommendations for the Basic Policy on Economic and Fiscal Management and Reform 2024 to promote infectious disease control measures in combating antimicrobial resistance (AMR). An introduction of these recommendations was featured in GemMed online on June 19th. >> For more information https://lnkd.in/g83pANE9

The World Health Organization’s (WHO) high-priority meeting on antimicrobial resistance (AMR) today during the United Nations General Assembly draws much-needed attention to the increasing threat of AMR to public health worldwide. We take pride in being one of the few companies investing in new antibiotic therapies targeting high-priority, drug-resistant pathogens such as Acinetobacter baumannii and the more common Neisseria gonorrhea to improve patient outcomes and reduce the spread of disease. For more information, learn about our partnership with the Global Antibiotic Research & Development Partnership (GARDP) and our joint efforts to decrease the spread of drug-resistant gonorrhea worldwide. https://lnkd.in/dxaQpTS9

Before the Olympics end, we have an Antimicrobial Resistance (#AMR) Olympics meme for you. :) AMR should be trending, too, as one of the world's greatest global health crises. In the 2024 The Lancet Series on AMR, written by a group of experts brought together by OHT's Ramanan Laxminarayan, the authors show that pushing interventions we know, including universal water, sanitation, and hygiene access (#WASH); childhood vaccines; and infection control and prevention in hospitals could stop 750,000 deaths related to drug-resistant infections every year. AMR is an urgent issue, but we can take action and make a difference now! Ahead of the United Nations General Assembly High-Level Meeting on AMR, the Lancet series proposes global targets to reach by 2030 of a 10% reduction in deaths from AMR by reducing misuse of antibiotics in humans by 20% and in animals by 30% (10-20-30 by 2030) to ensure action is taken globally to address this growing problem. Learn more in the Lancet Series here: https://lnkd.in/dyU7eASR #Olympics #Paris2024 #AMR #UNGA

The World Health Organization’s (WHO) high-priority meeting on antimicrobial resistance (AMR) today during the United Nations General Assembly draws much-needed attention to the increasing threat of AMR to public health worldwide. We take pride in being one of the few companies investing in new antibiotic therapies targeting high-priority, drug-resistant pathogens such as Acinetobacter baumannii and the more common Neisseria gonorrhea to improve patient outcomes and reduce the spread of disease. For more information, learn about our partnership with the Global Antibiotic Research & Development Partnership (GARDP) and our joint efforts to decrease the spread of drug-resistant gonorrhea worldwide. https://lnkd.in/dxaQpTS9

With the G7 Leaders Summit currently underway in Italy we are very excited to have contributed to the Think7 Italy Communiqué "One World, One Health. A Strategic Vision for a Resilient Global Health System"! In our section of the brief on Antimicrobial Resistance we focus on the need for investing in improved global infrastructure for R&D and access to effective antimicrobials, as well as increasing surveillance capacity and infection prevention and control. Our high-level recommendations include: 🔹 Strengthen global antimicrobial R&D and access infrastructure through increased push funding, particularly through Global Antibiotic R&D Partnership (GARDP) and CARB-X. 🔹 Support and provide funding for innovative mechanisms, institutions and models aimed at ensuring timely access, registration, manufacturing and procurement of antimicrobials (such as the SECURE initiative). 🔹 Commit to a coordinated approach to financing and supporting pull incentive schemes, considering global needs for R&D and access. The full brief can be accessed here on the Think7 website: https://lnkd.in/eDEC87TT We have also put forward additional details for each of our recommendations on our own website: https://lnkd.in/etBx3JeV With many thanks to my collaborators on the brief for your valuable input and guidance. Jennifer Cohn Rohit Malpani Akhil Bansal STEFANO VELLA, MD Aanika Dalal

ARMoR recently had the opportunity to contribute to the Think7 Italy Communiqué "One World, One Health. A Strategic Vision for a Resilient Global Health System". In our section of the brief on Antimicrobial Resistance, we discuss how G7 leaders have made commitments to tackle AMR since 2014 but that we are yet to see these commitments translate into the policies needed to ensure patients can access effective treatments. We highlight the need for improved global infrastructure for R&D and access to effective antimicrobials, as well as increasing surveillance capacity and infection prevention and control. Our high-level recommendations include: 🔹 Strengthen global antimicrobial R&D and access infrastructure through increased push funding, particularly through GARDP and CARB-X. 🔹 Support and provide funding for innovative mechanisms, institutions and models aimed at ensuring timely access, registration, manufacturing and procurement of antimicrobials (such as the SECURE initiative). 🔹 Commit to a coordinated approach to financing and supporting pull incentive schemes, considering global needs for R&D and access. The full brief can be accessed here on the Think7 website: https://lnkd.in/eDEC87TT We have also put forward additional details for each of our recommendations on our own website: https://lnkd.in/etBx3JeV